Vyleesi
| Chemical Name | bremelanotide |
| Dosage Form | Injectable (subcutaneous; 1.75 mg/0.3 mL) |
| Drug Class | Receptor agonists |
| System | Female reproductive |
| Company | AMAG Pharmaceuticals |
| Approval Year | 2019 |
Indication
- Vyleesi is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance.